ALE.P03

PreclinicalSmall molecule

AAlentis Therapeutics AG

ALE.P03 is one of 5 small molecule programs targeting Cervical Squamous Cell Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical Squamous Cell CarcinomaRecruiting

Cervical Squamous Cell CarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

4 competitors in Cervical Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Taxol

Teva

Approved

—2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 3

Taxotere

Paraplatin

ALE.P03

AAlentis Therapeutics AG

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

PreclinicalRecruiting

Cervical Squamous Cell Carcinoma

NCT07169734

Clinical

Trials by Indication[1]

Cervical Squamous Cell Carcinoma1 trial

A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Recruiting·AAlentis Therapeutics AG·Preclinical·NCT07169734·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALE.P03. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALE.P03 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALE.P03. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alentis Therapeutics AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAlentis Therapeutics AG

ALE.P03

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Cervical Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News